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Abstract
Background:  Genetic variations in MBL2  that reduce circulating levels and alter functional
properties of the mannose binding lectin (MBL) have been associated with many autoimmune and
infectious diseases. We examined whether MBL2 variants influence the outcome of hepatitis C
virus (HCV) infection.
Methods: Participants were enrolled in the Urban Health Study of San Francisco Bay area injection
drug users (IDU) during 1998 through 2000. Study subjects who had a positive test for HCV
antibody were eligible for the current study. Participants who were positive for HCV RNA were
frequency matched to those who were negative for HCV RNA on the basis of ethnicity and
duration of IDU. Genotyping was performed for 15 single nucleotide polymorphisms in MBL2.
Statistical analyses of European American and African American participants were conducted
separately.
Results: The analysis included 198 study subjects who were positive for HCV antibody, but
negative for HCV RNA, and 654 IDUs who were positive for both antibody and virus. There was
no significant association between any of the genetic variants that cause MBL deficiency and the
presence of HCV RNA. Unexpectedly, the MBL2 -289X promoter genotype, which causes MBL
deficiency, was over-represented among European Americans who were HCV RNA negative (OR
= 1.65, 95% CI 1.05–2.58), although not among the African Americans.
Conclusion: This study found no association between genetic variants that cause MBL deficiency
and the presence of HCV RNA. The observation that MBL2 -289X was associated with the absence
of HCV RNA in European Americans requires validation.
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Background
Mannose binding lectin (MBL) is an acute phase reactant
that is secreted from the liver and is critical in host
defenses against a spectrum of bacterial, fungal, viral, and
parasitic pathogens. MBL directly mediates opsonophago-
cytosis and acvation of the C-type lectin complement
pathway by binding microbial mannose and N-acetylglu-
cosamine surface residues. MBL deficiency has been asso-
ciated with a range of auto-immune and infectious
diseases, including HIV-1 and hepatitis B viral infections
[1-4].
Low circulating levels of MBL have been associated with
common genetic variants in the MBL2 gene, which is the
only functional human gene for MBL. MBL2 is located on
the long arm of chromosome 10 (10q11.2-11) and con-
sists of four exons [5]. Exon 1 includes three nonsynony-
mous single nucleotide polymorphisms (SNPs), known
as D, B and C alleles, that alter the function as well as cir-
culating levels of MBL [6,7]. These SNPs, in combination
with two proximal promoter variants (-618H/L and -
289Y/X) [8,9] and a variant in the 5' untranslated region
(UTR) of MBL2 (-65Q/P) [6], form seven well-character-
ized 'secretor' haplotypes that alter functional activity,
namely, opsonophagocytosis, complement-activation
and circulating levels of MBL [10].
In the United States, chronic hepatitis C virus (HCV)
infection is a leading cause of cirrhosis, end-stage liver dis-
ease and hepatocellular carcinoma. The medical literature
on MBL and HCV infection is limited. Most previous stud-
ies focus on the relationship between MBL2 variants and
either response to antiviral treatment or the risk of devel-
oping fibrosis/cirrhosis [11]. In the present study, we eval-
uated whether common variations in MBL2 influence the
spontaneous resolution of HCV infection in a population
of injection drug users (IDU).
Methods
Study population
The present analysis is part of a comprehensive evaluation
of the relationship between human genetics and HCV
infection among IDUs enrolled in the Urban Health Study
(UHS). As previously described [12], participants enrolled
in UHS were recruited from street settings in six inner-city
San Francisco Bay area neighborhoods. All persons 18
years of age or older were eligible for enrollment if they
had injected drugs within the past 30 days or previously
participated in the Urban Health Study. New participants
were screened for visible signs of recent or chronic injec-
tion (i.e., recent venipuncture sites or scars). After the par-
ticipant provided written informed consent, a blood
sample and responses to a questionnaire were collected.
Study procedures were approved by Committee on
Human Subjects Research at University of California, San
Francisco and the Institutional Review Board of the
National Cancer Institute.
Participants enrolled in the UHS from 1998 through 2000
who had a positive test for HCV antibody were eligible for
the current study, which is a case-control study based on
cross-sectional data. These participants were tested for
HCV RNA. Those positive for HCV RNA were frequency
matched (maximum 4:1 ratio) to those who were negative
for HCV RNA on the basis of self-reported ethnic back-
ground and duration of IDU (± 5 years). Because IDUs
had very limited access to anti-HCV treatment at the time
of subject recruitment [13,14], it is highly likely that the
HCV RNA negative subjects in this study had recovered
spontaneously. Participants who were positive for HBV
surface antigen (HBsAg) were later excluded from the
analyses because of the complex relationship between
HCV infection and HBV infection in this population [24].
The subjects of this analysis consisted of 198 HCV RNA
negative participants (109 European Americans and 89
African Americans) and 654 HCV RNA positive partici-
pants (344 European Americans and 310 African Ameri-
cans).
Laboratory methods
Viral assays
We detected HCV antibodies using the HCV EIA version 3
(Ortho Diagnostics, Raritan, NJ), HCV RNA by a
branched-chain DNA assay (HCV bDNA version 3.0,
Bayer, Tarrytown, NY; analytic sensitivity, 2.5 × 103 cop-
ies/ml) and HBsAg with the Genetic Systems HBsAg EIA
(Bio-Rad, Redmond, WA). We tested for antibodies to
HIV-1 infection in plasma using the Genetic Systems rLAV
EIA assay (Bio-Rad, Redmond, WA). Reactive samples
were confirmed by HIV-1 Western Blot (Cambridge Bio-
tech, Worcester, MA).
Genotyping
Based on recent resequencing of MBL2, we selected fifteen
SNPs from exonic, intronic and promoter regions of
MBL2 to include loci that were previously associated with
circulating MBL levels and to capture haplotype diversity
in both the 5' and 3' blocks (Table 1) [15,16]. Information
on all assays is publicly available (including primers,
probes and conditions) on the SNP500 Cancer website
[17,18]. Details of the nomenclature used to describe
these sequence variations are also available [19,20]. We
extracted genomic DNA from cryopreserved lymphocytes
using a modified salt precipitation-extraction method
(Gentra Systems, Minneapolis, MN) or from granulocytes
using a silica membrane binding method (Qiagen Inc.,
Valencia, CA). Genotyping was performed using opti-
mized TaqMan™ assays and analyzed on the ABI 7900HT
platform (ABI, Foster City, CA). We identified duplicate
subjects with the AmpFLSTR Profiler Plus® PCR amplifica-BMC Infectious Diseases 2008, 8:57 http://www.biomedcentral.com/1471-2334/8/57
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tion kit (PE Applied Biosystems, Foster City, CA) to type
nine tetranucleotide short tandem repeat loci and the
Amelogenin locus. A blinded duplicate analysis of 5% of
study samples demonstrated greater than 99% concord-
ance.
Statistical analysis
All analyses were conducted separately among European
American and African American participants. We first
examined departure from Hardy-Weinberg proportions
for each locus among the participants that were positive
for HCV RNA and then evaluated differences in genotype
frequencies by HCV RNA status. We estimated the relative
risk of being HCV RNA negative using the prevalence odds
ratio (OR) and corresponding 95% confidence interval
(CI) calculated with logistic regression adjusted for sex,
duration of IDU and HIV-serostatus. Consistent with
some previous studies of HCV outcome, we examined
odds ratios for being HCV negative because it is the rarer
outcome. We did not include age in the regression models
because in UHS subjects this variable is highly correlated
with duration of IDU. The Pearson χ2 test was used to cal-
culate p-values; p 0.05 (two-tailed) was considered statis-
tically significant.
The seven classical secretor haplotypes (HYPA, LYPA,
LYQA, LXPA, HYPD, LYPB and LYQC; Table 1) were ana-
lyzed based on prior studies that demonstrated associa-
tions with circulating levels of MBL. Overall heterogeneity
(global score test) and individual secretor haplotype fre-
quencies, adjusted for covariates (sex, duration of IDU
and HIV-1 infection), were estimated by the expectation-
maximization progressive insertion algorithm (Haplo-
Stats version 1.1.0), as previously described [21]. This
method is based on empirical distributions of a minimum
of 10,000 and maximum of 50,000 permutations. We also
examined diplotypes formed by the Y/X promoter variant
and the three common structural variants from exon 1
[10,16]. The wild-type structural allele is designated as "A"
and the nonsynonymous SNPs (D, B and C) are desig-
nated as "O".
Results
Characteristics of the study population are described in
Table 2. Of the 453 European American participants,
those who were HCV RNA negative did not notably differ
from those who were HCV RNA positive with regard to
age (median: 43 years in each group) or duration of IDU
(median: cleared 23 years; chronic, 24 years). Male gen-
der, however, was more common among HCV RNA posi-
tive participants (71.8%) compared to those who were
HCV RNA negative (62.4%; p = 0.06). In addition, HIV-1
infection was more common among European American
participants who were HCV RNA positive (11.9%) com-
pared to those who were HCV RNA negative (4.6%; p =
0.03).
Among the 399 African Americans included in this inves-
tigation, participants who were HCV RNA negative were
similar to those who were HCV RNA positive with regard
to age (median: 47 years in each group), duration of IDU
(median: cleared 26 years; chronic, 27 years), gender
(males: chronic, 61.9%; cleared, 60.7%) and HIV-1 infec-
tion (chronic HCV infection, 11.6%; cleared, 9.0%).
HCV RNA and MBL2 genotypes
In separate evaluations of the European American and
African American participants who were positive for HCV
RNA, genotypic distributions for all fifteen variants were
consistent with Hardy-Weinberg proportions (P ≥ 0.05;
Table 1: Common variants of MBL2 genotyped in the Urban Health Study
Variant dbSNP Identifier Secretor* Amino Acid Change Function
T-1964C rs1031101
G-618C rs11003125 H/L (aka -550) H = high, L = low
G-289C rs7096206 Y/X (aka -221) Y = high, X = low
T-65C rs7095891 Q/P (aka +4)
Ex1 C-34T rs5030737 A/D (Codon 52) R52C D = low
Ex1 G-27A rs1800450 A/B (Codon 54) G54D B = low
Ex1 G-18A rs1800451 A/C (Codon 57) G57E C = low
IVS2 G-630A rs4935046
IVS2 T-250C rs1838066
IVS3 G-28C rs930508
Ex4 C+5G rs930507
Ex4 T-1483C rs10082466
Ex4 G-1067A rs10824792
Ex4 G-901A rs2120132
Ex4 G-710A rs2099902
NOTE: Six common variants form secretor haplotypes including -618, -289, -65, Ex1 -34, Ex1 -27, Ex1 – 18. Nomenclature for description of 
sequence variations is described in http://snp500cancer.nci.nih.gov/terms_snp_region.cfmBMC Infectious Diseases 2008, 8:57 http://www.biomedcentral.com/1471-2334/8/57
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Table 3). Among European American participants, the -
289C-containing variant (-289X) of the proximal pro-
moter, which causes MBL deficiency, was over-repre-
sented among those who were HCV RNA negative
compared to participants who were positive for HCV RNA
(OR = 1.65, 95% CI 1.05–2.58). There were no notable
associations with the other promoter variants that have
been previously shown to alter MBL levels [G618C (H/L)
or T65C (P/Q)] or with either structural locus commonly
found among European Americans (D or B). Associations
with other MBL2 variants did not achieve statistical signif-
icance.
In contrast to our observation among European American
participants, the -289C (low promoter) genotype was
unrelated to HCV RNA status among African American
participants (OR, 0.97; P = 0.94). Homozygosity for the C
allele of the T-1483C exon 4 polymorphism, which is a
synonymous variant without established functional
effects, was associated with a two-fold increased likeli-
hood of being HCV negative in the African Americans, but
there was no overall association for 1483C carriers (OR,
1.05; 95% CI, 0.62–1.79). HCV clearance among African
American participants was not significantly associated
with other promoter, structural or intronic variants of
MBL2.
HCV RNA and haplotypes of MBL2
Among European Americans, the LXPA haplotype (the
only secretor haplotype containing -289C [X]) was associ-
ated with an increased likelihood of being negative for
HCV RNA when compared to the HYPA haplotype (Table
4; OR = 1.73, 95% CI 1.10–2.74; p = 0.01). LXPA is asso-
ciated with lower MBL levels compared to HYPA. In an
additive model, each copy of LXPA was associated with a
nearly 2-fold increase in risk (P-trend = 0.01). Among
African American participants, there were no significant
associations of secretor haplotypes and HCV RNA.
We next examined the relationship between the MBL2 Y/
X, A/0 diplotypes and HCV RNA (Table 5), comparing
participants who carried YA/YA, which has been associ-
ated with the highest MBL levels, to participants with
other diplotypes in descending order of previously associ-
ated serum MBL levels. Among European American partic-
ipants, those with XA/YO were more likely to be HCV
RNA negative (OR, 2.31; 95% CI, 1.07–5.02). Collapsing
the diplotypes into four categories based on a previous
report of MBL levels [15], participants in the lowest cate-
gory (XA/YO and YO/YO) were more likely to be HCV
RNA negative than those in the highest category (YA/YA
diplotype; OR, 2.00; 95% CI, 1.05–3.82). Participants in
intermediate categories were no more likely to be HCV
RNA negative than those with the YA/YA diplotype. There
were no notable associations of any MBL Y/X, A/0 diplo-
type and HCV RNA among African American participants
(Table 5).
Discussion
In this study, MBL2 genotypes or haplotypes associated
with MBL deficiency were not, in general, associated with
the likelihood of being negative for HCV RNA. Among
European Americans, the -289C (X) promoter variant,
which is associated with moderately lower MBL levels,
was actually more common in participants who were neg-
ative for HCV RNA than those who were positive. Among
African Americans, there was no compelling evidence of
HCV RNA status with any of the MBL2 genotypes or hap-
lotypes evaluated. To our knowledge there are no previous
studies of common variation in MBL2 and spontaneous
clearance of HCV infection to corroborate these results
[11], but the size of the study, our multiethnic population
and gene coverage suggest that clearance of HCV infection
is not impaired by MBL insufficiency.
The association of HCV RNA negative status with MBL2 -
289C (X) [and LXPA, the haplotype associated with -
289C] among European Americans may be due to chance.
This 'protective effect' is contrary to most previous obser
Table 2: General demographic characteristics of the Urban Health Study population genotyped for common variants in MBL2
European Americans African Americans
HCV RNA Negative 
(n = 109)
HCV RNA Positive 
(n = 344)
P HCV RNA Negative 
(n = 89)
HCV RNA Positive 
(n = 310)
P
Gender, male (%) 68 (62.4) 247 (71.8) 0.06 54 (68.7) 192 (61.2) 0.83
Age at blood draw, median 
years (range)
43 (25–63) 43 (23–65) 0.46 47 (31–64) 47 (28–82) 0.16
Duration of IDU, median 
years (range)
23 (5–41) 24 (10–49) 0.83 26 (8–44) 27 (11–51) 0.13
HIV-1 serostatus
Seropositive 5 (4.6) 41 (11.9) 8 (9.0) 36 (11.6)
Seronegative 104 (95.4) 303 (88.1) 0.03 81 (91.0) 274 (88.4) 0.49BMC Infectious Diseases 2008, 8:57 http://www.biomedcentral.com/1471-2334/8/57
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Table 3: Common variants in MBL2 and odds ratio for being HCV RNA negative among injection drug users
European Americans African Americans
Locus Genotype HCV RNA
Negative
%H C V  R N A
Positive
% OR (95% CI) HCV RNA
Negative
%H C V  R N A
Positive
%O R  ( 9 5 %  C I )
T-1964C
TT 83 77.6 256 76.0 1.00 82 93.2 288 94.1 1.00
TC 23 21.5 73 21.7 0.94 (0.55–1.60) 6 6.8 17 5.6 1.27 (0.48–3.36)
CC 1 0.9 8 2.4 0.44 (0.05–3.51) 0 0.0 1 0.3 NA
TC + CC 24 22.4 81 24.0 0.91 (0.54–1.53) 6 6.8 18 5.9 1.20 (0.46–3.14)
G-618C (H/L)
CC 44 41.9 124 36.4 1.00 69 80.2 233 76.9 1.00
CG 47 44.8 164 48.1 0.80 (0.50–1.29) 15 17.4 67 22.1 0.76 (0.41–1.42)
GG 14 13.3 53 15.5 0.72 (0.36–1.43) 2 2.2 3 1.0 2.63 (0.42–16.43)
CG + GG 61 58.1 217 63.6 0.80 (0.51–1.26) 17 19.8 70 23.1 0.83 (0.46–1.50)
G-289C (Y/X)
GG 59 55.1 218 66.3 1.00 63 71.6 218 70.6 1.00
GC 42 39.3 103 31.3 1.56 (0.98–2.49) 23 26.1 87 28.2 0.92 (0.53–1.58)
CC 6 5.6 8 2.4 2.72 (0.90–8.23) 2 2.3 4 1.3 2.01 (0.35–11.42)
GC + CC 48 44.9 111 33.7 1.65 (1.05–2.58) 25 28.4 91 29.4 0.97 (0.57–1.63)
T-65C (P/Q)
CC 64 59.8 197 57.4 1.00 21 23.9 64 20.8 1.00
CT 38 35.5 127 37.0 0.93 (0.59–1.48) 43 48.9 160 51.9 0.81 (0.44–1.48)
TT 5 5.0 19 5.5 0.75 (0.27–2.09) 24 27.3 84 27.3 0.85 (0.43–1.67)
CT + TT 43 4.7 146 42.6 0.90 (0.58–1.40) 67 76.1 244 79.2 0.83 (0.47–1.47)
Ex1 C-34T (D)
CC 95 87.2 300 87.5 1.00 87 97.8 303 98.1 1.00
TC 13 11.9 42 12.2 1.06 (0.54–2.10) 2 2.3 6 1.9 1.11 (0.22–5.62)
TT 1 0.9 1 0.3 2.71 (0.16–45.25) 0 0.0 0 0.0 NA
TC + TT 14 12.8 43 12.5 1.00 (0.52–1.91) 2 2.3 6 1.9 1.11 (0.22–5.62)
Ex1 G-27A (B)
GG 85 78.0 256 75.5 1.00 83 93.3 285 93.4 1.00
GA 23 21.1 75 22.1 0.90 (0.53–1.53) 6 6.7 19 6.2 1.10 (0.42–2.86)
AA 1 0.9 8 2.4 0.42 (0.05–3.46) 0 0.0 1 0.3 NA
GA + AA 24 22.0 83 24.5 0.87 (0.52–1.46) 6 6.7 20 6.6 1.04 (0.40–2.70)
Ex1 G-18A (C)
GG 95 92.2 312 96.0 1.00 49 56.3 168 55.6 1.00
GA 8 7.8 13 4.0 2.26 (0.89–5.73) 29 33.3 116 38.4 0.86 (0.51–1.45)
AA 0 0.0 0 0.0 NA 9 10.3 18 6.0 1.68 (0.71–3.99)
GA + AA 8 7.8 13 4.0 2.26 (0.89–5.73) 38 43.7 134 44.4 0.97 (0.60–1.57)
IVS2 G-630A
GG 22 20.8 59 17.9 1.00 49 57.6 168 54.4 1.00
GA 55 51.9 161 48.8 0.89 (0.50–1.59) 31 36.5 127 41.1 0.84 (0.51–1.39)
AA 29 27.4 110 33.3 0.68 (0.36–1.30) 5 5.9 14 4.5 1.22 (0.41–3.60)
GA + AA 84 79.3 271 82.1 0.82 (0.47–1.43) 36 42.4 141 45.6 0.87 (0.54–1.42)
IVS2 T-250C
TT 42 40.4 119 35.6 1.00 72 80.9 236 76.9 1.00
TC 48 46.2 161 48.2 0.84 (0.52–1.36) 15 16.9 68 22.2 0.73 (0.39–1.36)
CC 14 13.5 54 16.2 0.72 (0.36–1.43) 2 2.3 3 1.0 2.52 (0.40–15.75)
TC + CC 62 59.6 215 64.4 0.83 (0.53–1.31) 17 19.1 71 23.1 0.79 (0.44–1.43)
IVS3 G-28C
GG 72 66.7 239 70.7 1.00 36 41.9 135 43.8 1.00
GC 34 31.5 93 27.5 1.28 (0.79–2.07) 39 45.3 144 46.8 1.02 (0.61–1.70)
CC 2 1.9 6 1.8 0.98 (0.19–5.00) 11 12.8 29 9.4 1.42 (0.65–3.14)
GC +CC 36 33.3 99 29.3 1.25 (0.78–1.99) 50 58.1 173 56.2 1.08 (0.66–1.76)
Ex4 C+5G
GG 70 66.7 244 71.6 1.00 41 46.1 143 46.6 1.00
GC 33 31.4 92 27.0 1.31 (0.81–2.14) 39 43.8 138 45.0 0.98 (0.60–1.62)
CC 2 1.9 5 1.5 1.17 (0.22–6.27) 9 10.1 26 8.5 1.22 (0.53–2.82)
GC + CC 35 33.3 97 28.4 1.32 (0.82–2.11) 48 53.9 164 53.4 1.02 (0.63–1.64)
Ex4 T-1483C
TT 65 60.2 193 58.5 1.00 25 28.7 88 29.6 1.00
TC 36 33.3 117 35.5 0.91 (0.57–1.47) 32 36.8 155 52.2 0.72 (0.40–1.30)
CC 7 6.5 20 6.1 1.13 (0.45–2.83) 30 34.5 54 18.2 2.02 (1.07–3.81)
TC + CC 43 39.8 137 41.5 0.94 (0.60–1.47) 62 71.3 209 70.4 1.05 (0.62–1.79)
Ex4 G-1067A
GG 18 17.5 46 13.8 1.00 62 72.9 199 65.9 1.00
GA 48 46.6 156 46.8 0.72 (0.38–1.37) 19 22.4 92 30.5 0.67 (0.38–1.20)
AA 37 35.9 131 39.3 0.65 (0.33–1.26) 4 4.7 11 3.6 1.31 (0.40–4.32)BMC Infectious Diseases 2008, 8:57 http://www.biomedcentral.com/1471-2334/8/57
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vations where MBL deficiency predisposed to a worsened
course of infection. In addition, MBL2 structural variants
were not significantly associated with HCV RNA negative
status among either European Americans or African Amer-
ican participants. Conversely, it should be noted that the
preservation of heterozygosity for MBL2 loci and the cor-
responding range of circulating MBL levels suggests that
low to moderate levels of MBL could be advantageous in
some circumstances [16]. In that regard, an association
between genotypes that produce low MBL levels and more
favorable outcome among patients with tuberculosis has
been reported [22]. The association of HCV RNA negative
status with MBL2  -289C (X) found among European
Americans in the present study requires replication.
We defined HCV outcome on the basis of results from a
single HCV EIA and a single HCV bDNA assay. False pos-
itive HCV EIA results are unlikely to have affected our
findings in a meaningful way because the high prevalence
of HCV antibodies found among IDUs combined with the
high specificity of the assay we used [23] yield a positive
predictive value exceeding 99%. Because this is a case-con-
trol study based on cross-sectional data, we could not use
the clinical definition of HCV "clearance" that is based on
the results of two HCV RNA assays at least 6 months apart.
It should also be noted that that we defined a positive
HCV RNA result on the basis of an assay with a detection
limit of 2500 copies/ml. In another analysis based on
these test results, Tseng et al [24] found that the relative
Table 4: Odds ratio for risk of being HCV RNA negative among European American and African American injection drug users, by 
MBL2 secretor haplotype profile.
Haplotype frequency estimates
Secretor Haplotype Total HCV RNA Negative HCV RNA Positive P OR (95% CI)
European Americans
-618 -289 -65 Ex1 -34 Ex1 -27 Ex1 -18
HYPA G G C C G G 32.3% 29.2% 33.2% 0.24 referent
LYQA C G T C G G 21.2% 18.5% 22.1% 0.23 0.93 (0.58–1.51)
LXPA C C C C G G 19.5% 25.2% 17.7% 0.01 1.73 (1.10–2.74)
LYPB C G C C A G 12.9% 11.5% 13.3% 0.49 0.93 (0.53–1.64)
HYPD G G C T G G 6.5% 6.9% 6.4% 0.66 1.19 (0.59–2.39)
LYPA C G C C G G 5.1% 5.0% 5.1% 0.94 0.92(0.40–2.13)
LYQC C G T C G A 2.5% 3.9% 2.0% 0.08 3.27 (1.18–9.05)
Global score statistic 0.14
African Americans
LYQA C G T C G G 27.3% 24.8% 28.0% 0.38 referent 
LYQC C G T C G A 25.7% 27.0% 25.3% 0.69 1.24 (0.76–2.01) 
LYPA C G C C G G 16.5% 18.4% 15.9% 0.49 1.24(0.70–2.21) 
LXPA C C C C G G 15.4% 15.6% 15.4% 0.89 1.23 (0.69–2.18) 
HYPA G G C C G G 10.7% 9.8% 10.9% 0.74 1.10 (0.57–2.12) 
LYPB C G C C A G 3.4% 3.4% 3.4% 0.91 1.15 (0.44–3.01) 
HYPD G G C T G G 1.0% 1.1% 1.0% 0.92 1.21 (0.23–6.29)
Global score statistic 0.98
Relative haplotype frequencies adjusted for sex, duration of injection drug use and HIV-1 serostatus.
Haplotypes appear in order of descending haplotype frequencies among the comparison group stratified by race.
P-value for LYPC among European Americans is not statistically signficant due to permutations based on small haplotype frequencies.
The global score test evaluates differences between cases and controls in the overall haplotype distribution.
GA +AA 85 82.5 287 86.2 0.70 (0.38–1.28) 23 27.1 103 34.1 0.73 (0.43–1.25)
Ex4 G-901A
AA 61 58.1 187 57.0 1.00 26 29.2 90 29.8 1.00
GA 37 35.2 118 36.0 0.97 (0.60–1.55) 35 39.3 160 53.0 0.75 (0.42–1.33)
GG 7 6.7 23 7.0 1.02 (0.41–2.52) 28 31.5 52 17.2 1.87 (0.99–3.53)
GA + GG 44 41.9 141 43.0 0.69 (0.61–1.51) 63 70.8 212 70.2 1.03 (0.61–1.73)
Ex4 G-710A
AA 65 60.7 196 58.3 1.00 18 20.2 65 21.3 1.00
GA 34 31.8 120 35.7 0.86 (0.54–1.39) 34 38.2 150 49.2 0.82 (0.43–1.56)
GG 8 7.5 20 6.0 1.31 (0.55–3.17) 37 41.6 90 29.5 1.50 (0.78–2.88)
GA + GG 42 39.3 140 41.7 0.92 (0.59–1.44) 71 79.8 240 78.7 1.07 (0.60–1.93)
NOTE: The most frequent homozygotes among controls served as the referent. Genotypic odds ratios were adjusted for sex, duration of injection drug use, and HIV-
serostatus; OR (odds ratio); 95% CI (confidence interval); and NA, not applicable.
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risks in UHS for previously reported predictors of chronic
HCV infection (i.e., older age, African ancestry, presence
of HBsAg, HIV infection) were very consistent with studies
of 'HCV clearance' [25]. We are confident, therefore, that
our study design is able to detect true differences in HCV
outcome. We do not believe that our results are con-
founded by gender or HIV-1 status as we controlled for
these variables in logistic regression models. The number
of HIV-1-infected subjects in the study was too few for a
meaningful evaluation of the independent effect of the
MBL2 variants on HIV-1 serostatus.
Conclusion
In summary, our results suggest that HCV clearance is not
among the infectious outcomes for which variants of
MBL2  that cause MBL deficiency are deleterious. Our
unexpected observation that MBL2 -289X was associated
with the absence of HCV RNA in European Americans
requires validation in other populations.
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